pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

4,920 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT1873Endpoints1452Fierce Biotech770BioSpace761BioPharma Dive549raps249onclive165fda recalls120
therapy area
allOncology12965Rare Disease3357Immunology3052Cardiology2859Hematology2304Pulmonology2255Vaccines
  • FDA approves Regeneron's first siRNA therapy for generalized myasthenia gravis
    The FDA has granted approval for Regeneron's siRNA drug Livsayis (cemdisiran) for adult patients with generalized myasthenia gravis who are positive for anti‑acetylcholine receptor antibodies. Thi…
    BioSpace · 1h agoApprovalPositive↗ source
  • FDA approves Regeneron's Livsayis, first RNAi therapy for generalized myasthenia gravis
    The Food and Drug Administration approved Regeneron's Livsayis, an RNA interference drug for generalized myasthenia gravis, marking the company's first marketed RNAi therapy. The drug, originally…
    BioPharma Dive · 1h agoApprovalPositive↗ source
← prev
page 1 of 197
next →
fda medwatch115
globenewswire health73
fda press62
1861
Psychiatry & CNS1234
Ophthalmology1138
Endocrinology & Metabolism809
Pain792
Nephrology787
  • FDA approves Regeneron's siRNA drug Livsayis for myasthenia gravis, expanding its neurology portfolio
    Regeneron has received FDA clearance for its siRNA‑based therapy cemdisiran, now marketed as Livsayis, to treat myasthenia gravis. This approval is the second new myasthenia gravis drug cleared by…
    Endpoints · 2h agoApprovalPositive↗ source
  • Merck partners with Isomorphic Labs to use AI for discovering oncology drug candidates
    Merck announced a research collaboration with Isomorphic Labs, an artificial‑intelligence drug design firm, to explore small‑molecule candidates aimed at an undisclosed oncology target. Isomorphic…
    STAT · 3h agoDealPositive↗ source
  • Merck teams with Isomorphic Labs to discover new oncology small-molecule candidates
    Merck and Isomorphic Labs announced a research collaboration aimed at discovering small-molecule drugs for an undisclosed oncology target. The partnership will combine Isomorphic’s AI-driven drug…
    STAT · 5h agoDealPositive↗ source
  • AbbVie signs up to $2.5 B licensing deal with DISCO to develop solid tumor bispecific therapies
    AbbVie announced a licensing agreement with European biotech DISCO Pharmaceuticals that could be worth as much as $2.5 billion. The deal includes a $40 million upfront payment and future milestones…
    BioSpace · 9h agoDealPositive↗ source
  • AbbVie partners with Disco Pharmaceuticals on up to $2.5 billion solid tumor deal
    AbbVie announced a partnership with Disco Pharmaceuticals, a preclinical cancer biotech based in Cologne, Germany, to advance antibody‑drug conjugate and T cell engager programs targeting solid tum…
    Endpoints · 9h agoDealPositive↗ source
  • Novartis reports mid-stage eczema drug success, plans to restart autoimmune CAR-T trials and narrows sales growth outlook
    Novartis said its experimental eczema treatment achieved a positive result in a mid-stage study, marking the company's first major clinical milestone in the skin-disorder area this year. The compa…
    Endpoints · 1h agoPositive readoutNeutral↗ source
  • Nine California biotech firms slash at least half of their workforces amid statewide cuts
    Workforce reductions have affected more than 1,000 biopharma employees in California so far this year, with the hardest hits falling on biotech firms. Nine companies have announced plans to cut at…
    BioSpace · 11h agoLayoffsNegative↗ source
  • Actinogen’s Alzheimer’s drug Xanamem fails pivotal trial, shares plunge over 80%
    Actinogen Medical, an Australian biotech, reported that its only candidate, Xanamem (emestedastat), did not meet the primary endpoint in a Phase 2b/3 study in patients with mild to moderate Alzheim…
    BioSpace · 1h agoNegative readoutNegative↗ source
  • Eli Lilly pilots virtual clinician platform to speed Alzheimer’s diagnosis
    Eli Lilly is testing a new virtual‑clinician service aimed at accelerating the diagnosis and early care for people showing signs of Alzheimer’s disease. The approach allows individuals with memory…
    Endpoints · 2h agoPositive↗ source
  • National Academies urges faster retractions and corrections to protect scientific record
    The National Academies of Sciences, Engineering, and Medicine released a report urging the scientific community to act more quickly when errors or data manipulation are identified in published rese…
    STAT · 58m agoPositive↗ source
  • FDA puts drug repurposing front-and-center, says BioSpace podcast
    In a recent episode of BioSpace’s podcast “Denatured,” host Jennifer C. Smith-Parker spoke with Daniel Tillett, chief executive of Racura Oncology, and Sten Sörensen, chief executive of Cereno Scie…
    BioSpace · 5h agoRegulatoryNeutral↗ source
  • MAHA PAC spent more on its own D.C. steakhouse events than on a key ally’s House race before midterm losses
    The political arm of Make America Healthy Again (MAHA) directed millions of dollars to its own operations, including a high‑profile dinner in Washington, D.C., rather than funneling that money to c…
    STAT · 7h agoNegative↗ source
  • Sanders says expanded Medicare plan may still pass despite Trump’s potential veto
    Senator Bernie Sanders told reporters that he is not certain a Trump veto would block an expanded Medicare for All proposal, suggesting the legislation could still move forward. The proposal appea…
    STAT · 3h agoNeutral↗ source
  • Erasca claims stronger, better-tolerated pan-RAS cancer drug based on early Chinese data
    Erasca, a U.S. biotech, says it has identified a pan-RAS inhibitor in China that it believes is more potent and better tolerated than Revolution Medicines’ Rasonque. The claim rests on limited dat…
    STAT · 5h agoNeutral↗ source
  • Study finds stopping statins in older adults may lead to worse outcomes despite non-inferior label
    A new trial called STREAM examined whether older adults without prior heart attacks or strokes could safely stop taking statins. The study was presented at the American Heart Association annual mee…
    STAT · 7h agoNegative readoutNeutral↗ source
  • Three series-C funded biotechs expand hiring, including Triveni Bio’s $65 M raise
    Three biotechnology companies that announced series C financing this year are actively hiring, signaling plans to scale operations. One of the firms secured a $140 million round and maintains offic…
    BioSpace · 11h agoDealNeutral↗ source
  • CLINUVEL to cut up to 20% of staff and move headquarters to New York
    CLINUVEL announced a strategic reorganization aimed at focusing resources on the U.S. market. The company will reduce its global workforce by 10% to 20%, affecting up to 21 of its 104 employees.…
    BioSpace · 1h agoLayoffsNegative↗ source
  • STAT+: Epic defends competitive practices; promises AI access to records
    In this edition of STAT Health Tech: EHR giant, Epic defends its competitive tactics, new data on AI and health care costs, and HLTH news.
    STAT · 2h ago↗ source
  • Sanofi secures first FDA approval to treat neurological symptoms in rare metabolic disease
    Sanofi’s Infilbray is designed to cross the blood-brain barrier, allowing the drug to prevent the toxic buildup of disease-causing lipids in the brain for patients with type 3 Gaucher disease.
    BioSpace · 2h ago↗ source
  • GSK receives FDA accelerated approval for neladalkib (Nelkarmi) in ALK-positive lung cancer, second win from Nuvalent deal
    GSK announced that the FDA has granted accelerated approval to its tyrosine kinase inhibitor neladalkib, to be sold under the brand name Nelkarmi, for patients with ALK‑positive non‑small cell lung…
    BioSpace · 1d agoApprovalPositive↗ source
  • Pfizer signs $2.6 billion China deal to develop in-vivo CAR-T therapies for autoimmune disease
    Pfizer announced a collaboration with Chinese biotech Starna Therapeutics to pursue in-vivo CAR-T cell therapies aimed at autoimmune disorders. Under the agreement, Pfizer will receive exclusive r…
    BioPharma Dive · 1d agoDealPositive↗ source
  • Pfizer partners with China's Starna Therapeutics on up to $2.6B in vivo CAR-T deal for autoimmune diseases
    Pfizer announced a collaboration with Chinese biotech Starna Therapeutics to develop in vivo CAR-T therapies targeting autoimmune diseases. The agreement covers three preclinical CAR-T programs, w…
    BioSpace · 1d agoDealPositive↗ source
  • White House withdraws Heidi Overton’s FDA commissioner nomination, raising uncertainty for agency’s future
    The White House pulled its nomination of Heidi Overton for FDA commissioner, a move that surprised members of the Senate health committee. Overton’s removal leaves the agency without a permanent h…
    STAT · 21h agoRegulatoryNegative↗ source